A Phase 2 Open-Label Study of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma (EMPOWER-CSCC-1): Final Long-Term Analysis of Groups 1, 2, and 3, and Primary Analysis of Fixed-Dose Treatment Group 6 Brett G. M. Hughes , Alexander Guminski , Samantha Bowyer , Michael R. Migden , Chrysalyne D. Schmults , Nikhil I. Khushalani , Anne Lynn S. Chang , Jean-Jacques Grob , Karl D. Lewis , George Ansstas , Fiona Day , Rahul Ladwa , Brian N. Stein , Eva Munoz Couselo , Friedegund Meier , Axel Hauschild , Dirk Schadendorf , Nicole Basset-Seguin , Badri Modi , Sophie Dalac-Rat , Lara A. Dunn , Lukas Flatz , Laurent Mortier , Sarah Guegan , Lucie M. Heinzerling , Janice M. Mehnert , Sabiha Trabelsi , Ainara Soria-Rivas , Alexander J. Stratigos , Claas Ulrich , Deborah J. Wong , Marie Beylot-Barry , Paolo Bossi , Cristina Buges Sanchez , Sunandana Chandra , Caroline Robert , Jeffery S. Russell , Ann W. Silk , Jocelyn Booth , Suk-Young Yoo , Frank Seebach , Israel Lowy , Matthew G. Fury , Danny Rischin JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY（2025）
Key words
advanced cutaneous squamous cell carcinoma, cemiplimab, clinical trials, fixed dose, immunotherapy, skin cancer, skin neoplasms
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
